The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
Open accessAbstract
The endocannabinoid system has been suspected to contribute to the association of visceral fat accumulation with metabolic diseases. We determined whether circulating endocannabinoids are related to visceral adipose tissue mass in lean, subcutaneous obese, and visceral obese subjects (10 men and 10 women in each group). We further measured expression of the cannabinoid type 1 (CB1) receptor and fatty acid amide hydrolase (FAAH) genes in paired samples of subcutaneous and visceral adipose tissue in all 60 subjects. Circulating 2-arachidonoyl glycerol (2-AG) was significantly correlated with body fat (r = 0.45, P = 0.03), visceral fat mass (r = 0.44, P = 0.003), and fasting plasma insulin concentrations (r = 0.41, P = 0.001) but negatively correlated to glucose infusion rate during clamp (r = 0.39, P = 0.009). In visceral adipose tissue, CB1 mRNA expression was negatively correlated with visceral fat mass (r = 0.32, P = 0.01), fasting insulin (r = 0.48, P < 0.001), and circulating 2-AG (r = 0.5, P < 0.001), whereas FAAH gene expression was negatively correlated with visceral fat mass (r = 0.39, P = 0.01) and circulating 2-AG (r = 0.77, P < 0.001). Our findings suggest that abdominal fat accumulation is a critical correlate of the dysregulation of the peripheral endocannabinoid system in human obesity. Thus, the endocannabinoid system may represent a primary target for the treatment of abdominal obesity and associated metabolic changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Self-citationThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Self-citationVan Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 1×
“If this hypothesis holds true, the calculated weight loss–independent effect of rimonabant treatment on circulating adiponectin levels could be explained on the adipocyte level (16).”
BackgroundPi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
Cota, D., Marsicano, G., Tschöp, M., Grübler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thöne-Reineke, C., Ortmann, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17725 · Cited by 1,168
Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J., Mackie, K., Offertáler, L., Wang, L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523057 · Cited by 1,101
Self-citationThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
Kirkham, T. C., Williams, C. M., Fezza, F., & Marzo, V. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704767 · Cited by 788
Endocannabinoid control of food intake and energy balance
Di Marzo, V., & Matias, I. (2005) · Nature Neuroscience · doi:10.1038/nn1457 · Cited by 743
Plasma Visfatin Concentrations and Fat Depot–Specific mRNA Expression in Humans
Berndt, J., Klöting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schön, M. R., Stumvoll, M., & Blüher, M. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2911 · Cited by 724
Self-citationActivation of the peripheral endocannabinoid system in human obesity
Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2838 · Cited by 686 · cited 6×
“On the other hand, our data for the most part confirm the findings from our first study in women with unknown fat distribution phenotypes but with no concomitant medications, with the same hormonal status, and with only small variation in age (21).”
BackgroundResultInfluentialMatias, I., Gonthier, M.-P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino, C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2679 · Cited by 656
Is visceral obesity the cause of the metabolic syndrome?
Després, J. (2006) · Annals of Medicine · doi:10.1080/07853890500383895 · Cited by 651
Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J. P., Le Fur, G., Oury-Donat, F., & Soubrié, P. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.908 · Cited by 593
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M., & Soubrié, P. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802583 · Cited by 583
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.-P., & Soubrié, P. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00545.2002 · Cited by 566
Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors
Williams, C. M., & Kirkham, T. C. (1999) · Psychopharmacology · doi:10.1007/s002130050953 · Cited by 505
A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding
Gómez, R., Navarro, M., Ferrer, B., Trigo, J. M., Bilbao, A., Del Arco, I., Cippitelli, A., Nava, F., Piomelli, D., & Rodrı́guez de Fonseca, F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09612.2002 · Cited by 486
Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats
Jamshidi, N., & Taylor, D. A. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704379 · Cited by 463
Jbilo, O., Ravinet‐Trillou, C., Arnone, M., Buisson, I., Bribes, E., Péleraux, A., Pénarier, G., Soubrié, P., Le Fur, G., Galiègue, S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3177fje · Cited by 346
Wang, L., Liu, J., Harvey-White, J., Zimmer, A., & Kunos, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336351100 · Cited by 340
Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension
Bátkai, S., Pacher, P., Osei-Hyiaman, D., Radaeva, S., Liu, J., Harvey-White, J., Offertáler, L., Mackie, K., Rudd, M. A., Bukoski, R. D., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143230.23252.d2 · Cited by 322
Self-citationEndogenous cannabinoid system as a modulator of food intake
Cota, D., Marsicano, G., Lutz, B., Vicennati, V, Stalla, G. K., Pasquali, R., & Pagotto, U. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802250 · Cited by 315
Liu, Y. L., Connoley, I. P., Wilson, C. A., & Stock, M. J. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802847 · Cited by 313
Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH)
Sipe, J. C., Waalen, J., Gerber, A., & Beutler, E. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802954 · Cited by 259
Lichtman, A. H., Hawkins, E. G., Griffin, G., & Cravatt, B. F. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.1.73 · Cited by 227
Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes
Roche, R., Hoareau, L., Bes-Houtmann, S., Gonthier, M.-P., Laborde, C., Baron, J.-F., Haffaf, Y., Cesari, M., & Festy, F. (2006) · Histochemistry and Cell Biology · doi:10.1007/s00418-005-0127-4 · Cited by 166
Gary‐Bobo, M., Elachouri, G., Scatton, B., Fur, G. L., Oury-Donat, F., & Bensaïd, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015040 · Cited by 160
Harrold, J. A., Elliott, J. C., King, P., Widdowson, P. S., & Williams, G. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03245-6 · Cited by 137
Gelfand, E. V., & Cannon, C. P. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.12.067 · Cited by 119
Leptin Activates the Anandamide Hydrolase Promoter in Human T Lymphocytes through STAT3
Maccarrone, M., Rienzo, M. D., Finazzi‐Agrò, A., & Rossi, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211248200 · Cited by 87
Release of anandamide from blood cells
Vogeser, M., Hauer, D., Azad, S. C., Huber, E., Storr, M., & Schelling, G. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.065 · Cited by 76
Perwitz, N., Faßhauer, M., & Klein, J. C. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-925401 · Cited by 66
Maccarrone, M., Fride, E., Bisogno, T., Bari, M., Cascio, M. G., Battista, N., Finazzi‐Agrò, A., Suris, R., Mechoulam, R., & Marzo, V. D. (2004) · Molecular Human Reproduction · doi:10.1093/molehr/gah130 · Cited by 61
Modulators of Endocannabinoid Enzymic Hydrolysis and Membrane Transport
Ho, W. ‐. V., & Hillard, C. J. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_6 · Cited by 30
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
Body Fat Distribution and Risk of Cardiovascular Disease: An Update
Després, J.-P. (2012) · Circulation · doi:10.1161/circulationaha.111.067264 · Cited by 1,481
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases
Hajer, G. R., van Haeften, T. W., & Visseren, F. L. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn387 · Cited by 1,410
The endocannabinoid system links gut microbiota to adipogenesis
Muccioli, G. G., Naslain, D., Bäckhed, F., Reigstad, C. S., Lambert, D. M., Delzenne, N. M., & Cani, P. D. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.46 · Cited by 691
Adipose Tissue Dysfunction in Obesity
Blüher, M. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1192044 · Cited by 662
Metadata
- Authors
- Blüher, M., Engeli, S., Klöting, N., Berndt, J., Fasshauer, M., Bátkai, S., Pacher, P., Schön, M. R., Jordan, J., & Stumvoll, M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-11-01
- Volume
- 55
- Issue
- 11
- Pages
- 3053-3060
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2104652079
- Cited by
- 530
- References
- 41
- FWCI
- 25.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.